Immix Biopharma Inc Stock Price, News & Analysis

Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company, has secured a strategic investment from Goose Capital, led by former Tanox CEO Dr. Nancy T. Chang. Dr. Chang's track record includes developing successful FDA-approved drugs like XOLAIR®, TROGARZO®, and EBGLYSS®, which have collectively generated over $5 billion in sales.

The investment aims to support Immix's development of cell therapies for AL Amyloidosis and other serious diseases, particularly the commercialization of NXC-201 for relapsed/refractory AL Amyloidosis. This strategic partnership brings valuable expertise to Immix, as Dr. Chang has significant experience in bringing drugs from invention through FDA approval and commercialization.

Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases, has announced its participation in the upcoming Stifel 2025 Healthcare Conference.

The conference will take place from November 11-13, 2025 at the Lotte New York Palace Hotel in New York. The company will conduct institutional investor meetings and one-on-one sessions during the event. Interested investors can arrange meetings through their Stifel representatives. A replay of the presentation will be available on the company's website under the Investors section.

Immix Biopharma (NASDAQ:IMMX) has announced its strategy for Other Serious Diseases (OSD) while advancing its lead BCMA-targeted CAR-T cell therapy, NXC-201. The company is currently conducting clinical trials for multiple serious diseases and plans to partner with external organizations to license out these OSD programs.

The company remains focused on completing the NEXICART-2 trial in relapsed/refractory AL Amyloidosis for Biologics License Application (BLA) submission. NXC-201 features a unique "digital filter" technology that filters out non-specific activation, potentially offering "one-and-done" treatment solutions. The company plans to present additional clinical data at upcoming scientific forums.

Immix Biopharma (NASDAQ:IMMX) announced promising safety data for its CAR-T therapy NXC-201, highlighting the absence of neurotoxicity in low-volume disease cases. The company is advancing its NEXICART-2 clinical trial towards a Biologics License Application (BLA) for treating relapsed/refractory AL Amyloidosis.

The therapy's favorable safety profile positions NXC-201 for potential expansion into other immune-mediated and serious diseases. Interim results were presented at ASCO 2025 by Dr. Heather Landau of Memorial Sloan Kettering Cancer Center, with the company maintaining focus on BLA submission for FDA approval.

Immix Biopharma (NASDAQ:IMMX) reported accelerated progress in its NEXICART-2 clinical trial for relapsed/refractory AL Amyloidosis. The trial has expanded to 18 clinical trial sites nationwide, marking significant advancement toward becoming the first FDA-approved cell therapy for this orphan indication.

The company presented interim results at ASCO 2025, with Dr. Heather Landau of Memorial Sloan Kettering Cancer Center leading the presentation. The expansion addresses an urgent unmet need, as currently there are no FDA-approved drugs for this condition.

Immix Biopharma (IMMX) participated in an exclusive FDA CEO Forum at FDA headquarters in Silver Spring, MD on June 5, 2025. The event, led by FDA Commissioner Marty A. Makary, M.D., M.P.H., aimed to gather input from biotech and pharmaceutical leaders on modernizing FDA's regulatory framework. The forum focused on supporting innovation and improving patient access to safe and effective therapies. Dr. Makary emphasized the importance of gathering feedback from industry leaders, while IMMX's CEO Dr. Ilya Rachman and CFO Gabriel Morris expressed appreciation for being selected alongside global pharmaceutical industry leaders to participate in this collaborative discussion.

Immix Biopharma (IMMX) announced positive interim results from its NEXICART-2 Phase 1/2 clinical trial of NXC-201 for relapsed/refractory AL Amyloidosis at ASCO 2025. The therapy met its primary endpoint with a remarkable 70% complete response rate (7/10 patients), significantly outperforming current treatments which typically achieve less than 10% CR. The remaining 3 patients showed bone marrow minimum residual disease negativity, suggesting potential future CRs. The trial demonstrated strong safety profile with no neurotoxicity, no relapses, and only low-grade cytokine release syndrome observed. Patients in the trial had received a median of 4 prior lines of therapy. Following treatment, all patients normalized pathological disease markers and showed cardiac and renal organ improvements. The company plans to submit a Biologics License Application (BLA) for FDA approval.

Immix Biopharma (IMMX) reports significant expansion of its NEXICART-2 clinical trial for relapsed/refractory AL Amyloidosis, with 14 U.S. sites now actively enrolling patients - adding 10 new sites since their last update. The company notes that patient enrollment is exceeding expectations and anticipates completing the trial ahead of schedule.

Additionally, Phase 1/2 interim readout data from the NEXICART-2 trial has been selected for oral presentation at ASCO 2025 (May 30 - June 3) in Chicago. The presentation will be delivered by Dr. Heather Landau, Director of Amyloidosis Program at Memorial Sloan-Kettering Cancer Center.

Immix Biopharma (IMMX) announced positive interim results from its NEXICART-2 Phase 1/2 clinical trial for NXC-201 in treating relapsed/refractory AL Amyloidosis. Key findings include a remarkable 71% complete response (CR) rate (5/7 patients), with the remaining 2 patients showing bone marrow minimum residual disease negativity. The trial demonstrated significant efficacy compared to current treatments, which typically show less than 10% CR rates. Notable safety outcomes include no neurotoxicity and only low-grade cytokine release syndrome lasting under 24 hours. The study involved patients with a median of 4 prior therapy lines (range: 2-9). Updated results will be presented at ASCO 2025 by Dr. Heather Landau of Memorial Sloan Kettering Cancer Center, followed by a KOL event discussing the findings.